[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657786":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":39,"studyPopulation":40,"armGroups":41,"interventions":35,"overallOfficials":45,"centralContacts":50,"locations":35,"responsibleParty":56,"collaborators":35,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":35,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":35,"enrollmentInfo":69,"targetDuration":35,"studyType":72,"phases":35,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":83,"whyStopped":35,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":35},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":35},[9],{"measure":10,"description":11,"timeFrame":12},"Prevalence of ocular surface disease","Proportion of patients with ocular surface disease defined as an Ocular Surface Disease Index (OSDI) score ≥13.","Baseline",[14,17,20,23,26,29,32],{"measure":15,"description":16,"timeFrame":12},"Proportion of Patients with Mild Ocular Surface Disease Symptoms","Proportion of patients with mild ocular surface disease symptoms defined as OSDI score 13-22.",{"measure":18,"description":19,"timeFrame":12},"Proportion of Patients with Moderate Ocular Surface Disease Symptoms","Proportion of patients with moderate ocular surface disease symptoms defined as OSDI score 23-32.",{"measure":21,"description":22,"timeFrame":12},"Proportion of Patients with Severe Ocular Surface Disease Symptoms","Proportion of patients with severe ocular surface disease symptoms defined as OSDI score 33-100.",{"measure":24,"description":25,"timeFrame":12},"Mean OSDI score","Mean Ocular Surface Disease Index score (range 0-100).",{"measure":27,"description":28,"timeFrame":12},"Tear film break-up time (TBUT)","Mean tear film break-up time in seconds.",{"measure":30,"description":31,"timeFrame":12},"Schirmer I test result","Mean Schirmer I test value in millimeters.",{"measure":33,"description":34,"timeFrame":12},"Corneal fluorescein staining score","Mean total corneal fluorescein staining score (range 0-15) according to the NEI\u002FIndustry Workshop grading scale.",null,{"allocation":35,"interventionModel":35,"interventionModelDescription":35,"primaryPurpose":35,"observationalModel":37,"timePerspective":38,"maskingInfo":35},"CASE_ONLY","CROSS_SECTIONAL","Long-term use of topical antiglaucoma medications may adversely affect the ocular surface. This observational study will include adult patients with glaucoma who have been using one or more topical antiglaucoma medications for at least 6 months.\n\nParticipants will complete the Ocular Surface Disease Index (OSDI) questionnaire and undergo clinical ocular surface assessment including tear film break-up time, Schirmer I test, and corneal fluorescein staining.","Adult patients with diagnosed glaucoma receiving long-term topical antiglaucoma medications at Assiut University Hospital and El Mabarra Hospital.",[42],{"label":43,"type":35,"description":44,"interventionNames":35},"Single cohort: Glaucoma patients on long-term topical therapy","Adult patients with glaucoma receiving topical antiglaucoma medications for at least 6 months who will undergo OSDI questionnaire and clinical ocular surface assessment.",[46],{"name":47,"affiliation":48,"role":49},"Mohamed s Abdel-rehim, prof","Ophthalmology Department, Assiut University Hospitals","STUDY_CHAIR",[51],{"name":52,"role":53,"phone":54,"phoneExt":35,"email":55},"Margo f Awad, Resident","CONTACT","+20 12 73302611","margo19.mahros@gmail.com",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Margo Mahrous Fawzy Awad","Principal Investigator","100657786","ocular-surface-disease-in-glaucoma-patients-on-long-term-therapy-100657786",false,"NCT07841912","Ocular Surface Disease in Glaucoma Patients on Long-Term Therapy","Prevalence and Severity of Ocular Surface Disease Among Adult Patients With Glaucoma on Long-Term Topical Antiglaucoma Medications","Inclusion Criteria:\n\n* \\- Age 18 years or older\n* Diagnosed glaucoma\n* Currently receiving one or more topical antiglaucoma medications\n* Duration of topical antiglaucoma treatment ≥6 months\n* Written informed consent\n\nExclusion Criteria:\n\n* \\- Current use of concomitant topical ocular medication that may affect the ocular surface (e.g., topical cyclosporine)\n* Previous ocular surgery within the preceding 6 months\n* History of corneal surgery or significant ocular trauma affecting the ocular surface\n* Active ocular infection or significant active ocular inflammation\n* Contact lens wear\n* Systemic autoimmune or connective tissue diseases known to affect the ocular surface (e.g., Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus)\n* Significant corneal pathology interfering with ocular surface assessment","ALL","18 Years",{"count":70,"type":71},55,"ESTIMATED","OBSERVATIONAL","This cross-sectional study aims to determine the prevalence and severity of ocular surface disease among adult patients with glaucoma receiving long-term topical antiglaucoma medications.",[75,76,77],"Glaucoma","Ocular Surface Disease","Dry Eye",[79,75,80,81,82],"Ocular surface disease","OSDI","Topical antiglaucoma medications","Assiut","NOT_YET_RECRUITING","2026-09-24",{"date":86,"type":87},"2026-09-28","ACTUAL",{"date":89,"type":71},"2026-09-26",{"date":91,"type":71},"2028-04-20",{"name":5,"class":6}]